Haemonetics (HAE) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended December 2025, Haemonetics (HAE) reported revenue of $338.97 million, down 2.8% over the same period last year. EPS came in at $1.31, compared to $1.19 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $334.17 million, representing a surprise of +1.44%. The company delivered an EPS surprise of +3.15%, with the consensus EPS estimate being $1.27.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Haemonetics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net revenues- United States: $247.71 million versus the two-analyst average estimate of $242.92 million. The reported number represents a year-over-year change of -3.9%.
• Net revenues- Rest of Asia: $23.03 million compared to the $30.22 million average estimate based on two analysts.
• Net revenues- Europe: $48.28 million versus $45.27 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.3% change.
• Net revenues- Japan: $18.14 million versus the two-analyst average estimate of $17.81 million. The reported number represents a year-over-year change of +12.1%.
• Net revenues- Plasma: $138.91 million versus $128.71 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.5% change.
• Net revenues- Hospital: $143.5 million versus the three-analyst average estimate of $152.91 million. The reported number represents a year-over-year change of -0.3%.
• Net revenues- Blood Center: $56.56 million versus the three-analyst average estimate of $52.97 million. The reported number represents a year-over-year change of -19.6%.
• Operating income- Plasma: $50.23 million compared to the $44.91 million average estimate based on two analysts.
• Operating income- Hospital: $25.92 million versus $31.53 million estimated by two analysts on average.
• Operating income- Blood Center: $13.03 million versus the two-analyst average estimate of $13.15 million.

View all Key Company Metrics for Haemonetics here>>>

Shares of Haemonetics have returned -20.5% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Haemonetics Corporation (HAE): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research